Search

Your search keyword '"Akarca, Ayse"' showing total 361 results

Search Constraints

Start Over You searched for: Author "Akarca, Ayse" Remove constraint Author: "Akarca, Ayse"
361 results on '"Akarca, Ayse"'

Search Results

1. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

4. ConCORDe-Net: Cell Count Regularized Convolutional Neural Network for Cell Detection in Multiplex Immunohistochemistry Images

5. Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

6. DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface

7. Self-supervised Antigen Detection Artificial Intelligence (SANDI)

8. Thyroid MALT lymphoma: self-harm to gain potential T-cell help

9. Self-supervised Antigen Detection Artificial Intelligence (SANDI)

10. Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature

11. Cancer Associated Bacteria in Primary and Metastatic Non-Small Cell Lung Cancer

12. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma

13. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

14. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress

16. Novel markers in pediatric-type follicular lymphoma

19. Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

20. Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer associated fibroblasts

21. ABCL-184 Impact of MYC and BCL2 Double Expression on Outcomes in Primary CNS Lymphoma: A UK Multicenter Analysis

22. POSTER: ABCL-184 Impact of MYC and BCL2 Double Expression on Outcomes in Primary CNS Lymphoma: A UK Multicenter Analysis

23. Correction to: Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program

24. Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program

26. Correction to: Single‑cell profiling of myasthenia gravis identifies a pathogenic T cell signature

28. CD47 expression in acute myeloid leukemia varies according to genotype

29. Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer

30. Figure 5 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

31. Figure 2 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

32. Table 1 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

33. Supplementary Data from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

34. Figure 4 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

35. Table S1 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

36. Data from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

37. Figure 6 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

38. Figure 1 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

39. Figure 3 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma

40. Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer

41. Data from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer

42. Data from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

43. Supplemental Figure 5 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

44. Data from Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

45. Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

46. Supplementary Data from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer

47. Supplementary Figure 4 from Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

48. TRACERx Consortium Members from Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

49. Supplemental Figure 7 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

50. Supplementary Figure 2 from Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

Catalog

Books, media, physical & digital resources